

Flerie divests its holding in A3P Biomedical

Stockholm, Sweden, March 6 2025. Flerie AB announces the divestment of all its shares in the portfolio company A3P Biomedical for a total consideration of SEK 71.3 million, representing a valuation 55% above the latest fair value reported by Flerie. After the divestment, Flerie's investment portfolio consists of 28 companies.

A3P Biomedical has developed Stockholm3, a blood-based diagnostic test that helps to determine the risk of developing aggressive prostate cancer in a more specific and sensitive manner than today's standard of care, PSA.

Flerie invested in A3P Biomedical in 2022 and has since been an active owner supporting the company's commercialisation process. During 2024, A3P Biomedical announced the launch of Stockholm3 through partnerships in the US, Switzerland and Germany.

"After contributing as active owners during the initial stage of A3P Biomedical's commercial development we believe now is the right time to divest our holding in the company. It is clear that A3P Biomedical has a great future ahead, but this opportunity will allow us to prioritise our core focus areas, namely development of therapeutics and pharma services. This naturally aligns with our strategy to continuously optimise the structure of our investment portfolio, while also providing our companies with the best opportunities for long-term success," comments Ted Fjällman, CEO of Flerie.

Prior to the divestment, Flerie's ownership in A3P Biomedical amounted to 8% and the holding was 1.1% of Flerie's Net Asset Value.

For more information:

Ted Fjällman, CEO
Email: ir@flerie.com

Flerie in brief

Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie's active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB's ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com

Attachments

[Flerie divests its holding in A3P Biomedical](#)